Clinical trial averages show semaglutide users losing 10-15% of body weight over 68 weeks, and tirzepatide users losing 15-22% of body weight over 72 weeks
Semaglutide was an ideal candidate for oral delivery with SNAC due to its low molecular weight (4,113.6 Da), long half-life (~ 7 days after subcutaneous administration), and high potency relative to other peptides [14, 40, 46, 56]
But restarting the same dose, I didnt really feel full, might be because I may be immune
Thats an expected adjustment as your body changes, not a sign of a problem
Final Comments: This is the first Brazilian report of metabolic syndrome associated with SH2B1-related monogenic obesity successfully treated with sleeve gastrectomy
Studies are also being done on whether it helps sleep apnea and liver inflammation, he said